SCHEMBL23069129

SCHEMBL23069129

CCN(CCc1c[nH]c2cccc(OC(C)=O)c12)C(C)C

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTR2A P28223 10/20 0.51
▸ HTR2C P28335 5/20 0.50
▸ HTR2B P41595 5/20 0.50
▸ HTR1A P08908 4/20 0.50
▸ HTR6 P50406 3/20 0.50
▸ MTNR1A P48039 1/20 0.48
▸ MTNR1B P49286 1/20 0.48
▸ HTR1D P28221 3/20 0.43
▸ HTR1B P28222 2/20 0.43
▸ HTR1E P28566 2/20 0.43
▸ HTR7 P34969 2/20 0.43
▸ HTR5A P47898 2/20 0.43
▸ DRD1 P21728 1/20 0.43
▸ ADORA2A P29274 1/20 0.43
▸ ADORA2B P29275 1/20 0.43
▸ DRD3 P35462 1/20 0.43
▸ SLC22A6 Q4U2R8 1/20 0.41
▸ HTR1F P30939 2/20 0.41
▸ HTR3E A5X5Y0 1/20 0.41
▸ HTR3B O95264 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27084868 0.91 HTR2A (0.51) HTR2AHTR2CHTR2BHTR1AHTR6
SCHEMBL27084798 0.91 HTR2A (0.56) HTR2AHTR2CHTR2BHTR1AHTR6
SCHEMBL26559690 0.90 MTNR1A (0.53) HTR2AHTR2CHTR2BHTR1AHTR6
SCHEMBL27084851 0.90 HTR2A (0.57) HTR2AHTR2CHTR2BHTR1AHTR6
SCHEMBL29403199 0.88 HTR2A (0.53) HTR2AHTR2CHTR2BHTR1AHTR6
SCHEMBL4210376 0.88 HTR2A (0.53) HTR2AHTR2CHTR2BHTR1AHTR6
SCHEMBL27084781 0.88 HTR2A (0.51) HTR2AHTR2CHTR2BHTR1AHTR6
SCHEMBL27084840 0.88 HTR2A (0.53) HTR2AHTR2CHTR2BHTR1AHTR6
SCHEMBL29633057 0.87 HTR6 (0.54) HTR2AHTR2CHTR2BHTR1AHTR6
SCHEMBL20970978 0.87 HTR6 (0.54) HTR2AHTR2CHTR2BHTR1AHTR6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220160737-A1 TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH TURTLE BEAR HOLDINGS LLC (US) 2022-05-26 — — US claimed
US-20260108544-A1 TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH TURTLE BEAR HOLDINGS LLC (US) 2026-04-23 — — US disclosed
US-20260048048-A1 TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH TURTLE BEAR HOLDINGS LLC (US) 2026-02-19 — — US disclosed
US-20250325533-A1 TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH TURTLE BEAR HOLDINGS LLC (US) 2025-10-23 — — US disclosed
US-12403150-B2 Tryptamine compositions for enhancing neurite outgrowth TURTLE BEAR HOLDINGS, LLC (US) 2025-09-02 — — US disclosed
US-20250205254-A1 TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH TURTLE BEAR HOLDINGS LLC (US) 2025-06-26 — — US disclosed
US-12257258-B2 Tryptamine compositions for enhancing neurite outgrowth TURTLE BEAR HOLDINGS, LLC (US) 2025-03-25 — — US disclosed
US-12171771-B2 Tryptamine compositions for enhancing neurite outgrowth TURTLE BEAR HOLDINGS, LLC (US) 2024-12-24 — — US disclosed
US-20240285609-A1 TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH TURTLE BEAR HOLDINGS LLC (US) 2024-08-29 — — US disclosed
US-20240285608-A1 TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH TURTLE BEAR HOLDINGS LLC (US) 2024-08-29 — — US disclosed
US-20220160737-A1 TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH TURTLE BEAR HOLDINGS LLC (US) 2022-05-26 — — US disclosed
US-20220125809-A1 TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH STAMETS PAUL EDWARD (US) 2022-04-28 — — US disclosed
US-20220125809-A1 TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH STAMETS PAUL EDWARD (US) 2022-04-28 — — US disclosed
US-20210251976-A1 TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH TURTLE BEAR HOLDINGS LLC (US) 2021-08-19 — — US disclosed
US-20210251976-A1 TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH TURTLE BEAR HOLDINGS LLC (US) 2021-08-19 — — US disclosed
WO-2021101926-A1 TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH STAMETS PAUL EDWARD (US) 2021-05-27 — — WO disclosed
US-20210145851-A1 TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH TURTLE BEAR HOLDINGS, LLC 2021-05-20 — — US disclosed
US-20210145851-A1 TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH TURTLE BEAR HOLDINGS, LLC 2021-05-20 — — US disclosed
US-20210069170-A1 TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH TURTLE BEAR HOLDINGS, LLC 2021-03-11 — — US disclosed
US-20210069170-A1 TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH TURTLE BEAR HOLDINGS, LLC 2021-03-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210251976-A1 TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH HTR1B, HTR6, BDNF HTR2A 11/4885HTR2C 6/4885HTR2B 9/4885
US-20210145851-A1 TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH HTR1B, HTR6, BDNF HTR2A 11/4885HTR2C 6/4885HTR2B 9/4885
US-12403150-B2 Tryptamine compositions for enhancing neurite outgrowth HTR1B, HTR6, BDNF HTR2A 11/4885HTR2C 6/4885HTR2B 9/4885
US-12257258-B2 Tryptamine compositions for enhancing neurite outgrowth HTR1B, HTR6, BDNF HTR2A 11/4885HTR2C 6/4885HTR2B 9/4885
US-20260048048-A1 TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH HTR1B, HTR6, BDNF HTR2A 7/4885HTR2C 4/4885HTR2B 5/4885
US-20240285609-A1 TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH HTR1B, BDNF, HTR6 HTR2A 9/4885HTR2C 7/4885HTR2B 8/4885
US-20220160737-A1 TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH HTR1B, HTR6, BDNF HTR2A 11/4885HTR2C 6/4885HTR2B 9/4885
US-20250325533-A1 TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH HTR1B, BDNF, HTR6 HTR2A 9/4885HTR2C 7/4885HTR2B 8/4885
US-20210069170-A1 TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH HTR1B, HTR6, BDNF HTR2A 11/4885HTR2C 6/4885HTR2B 9/4885
US-20220125809-A1 TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH HTR1B, HTR6, BDNF HTR2A 11/4885HTR2C 6/4885HTR2B 9/4885
US-12171771-B2 Tryptamine compositions for enhancing neurite outgrowth HTR1B, HTR6, BDNF HTR2A 11/4885HTR2C 6/4885HTR2B 9/4885
US-20250205254-A1 TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH HTR1B, HTR6, BDNF HTR2A 11/4885HTR2C 6/4885HTR2B 9/4885
US-20260108544-A1 TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH HTR1B, HTR6, BDNF HTR2A 9/4885HTR2C 5/4885HTR2B 8/4885
US-20240285608-A1 TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH HTR1B, BDNF, HTR6 HTR2A 9/4885HTR2C 7/4885HTR2B 8/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback